Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis.
BACKGROUND
Primary sclerosing cholangitis results in elevated but fluctuating serum alkaline phosphatase levels that occasionally return to normal.


OBJECTIVE
To investigate the frequency of normalization of alkaline phosphatase in newly diagnosed primary sclerosing cholangitis patients and the subsequent clinical outcomes.


METHODS
Records of newly diagnosed primary sclerosing cholangitis patients were examined retrospectively for laboratory values and clinical end points (cholangiocarcinoma, liver transplantation and death) within 10 years of diagnosis. Data from a recent prospective ursodeoxycholic acid treatment trial were also studied.


RESULTS
Eighty-seven patients met the inclusion criteria. Normalization of alkaline phosphatase was seen in 35 (40%) patients. Five (14%) patients with normalization reached an end point whereas 17 (33%) of the patients with persistent elevation reached an end point (P = 0.02). Ursodeoxycholic acid was used similarly by both groups. When the investigative criteria were applied to a prospective trial, there was again a significant relationship between normalization of alkaline phosphatase and survival in patients receiving ursodeoxycholic acid (P < 0.01) and the placebo group (P = 0.02).


CONCLUSIONS
Serum alkaline phosphatase was found to normalize in a high proportion of newly diagnosed primary sclerosing cholangitis patients. This was significantly associated with a better prognosis in a retrospective cohort and when data from a prospective treatment trial was evaluated.
Department of Medicine, Mayo Clinic, Rochester, MN 55901, United States.
Peter P
PP
Stanich
Einar
E
Björnsson
Andrea A
AA
Gossard
Felicity
F
Enders
Roberta
R
Jorgensen
Keith D
KD
Lindor
D000328:Adult; D000469:Alkaline Phosphatase / Q000097:blood*; D015415:Biomarkers / Q000097:blood*; D015209:Cholangitis, Sclerosing / Q000188:drug therapy / Q000201:enzymology; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016016:Proportional Hazards Models; D011446:Prospective Studies; D012016:Reference Values; D012189:Retrospective Studies; D015996:Survival Rate; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use*
D015415:Biomarkers; D014580:Ursodeoxycholic Acid; D000469:Alkaline Phosphatase
Gastroenterology. 1988 Nov;95(5):1395-8
3169503
Mayo Clin Proc. 2000 Jul;75(7):688-94
10907383
Gastroenterology. 1980 Aug;79(2):200-6
7399227
J Hepatol. 1997 Mar;26(3):560-6
9075663
N Engl J Med. 1997 Mar 6;336(10):691-5
9041099
Gastroenterology. 2006 Mar;130(3):715-20
16530513
Hepatology. 1999 Nov;30(5):1121-7
10534330
Hepatogastroenterology. 1999 Jan-Feb;46(25):136-41
10228778
Hepatology. 2009 Sep;50(3):808-14
19585548
Gastroenterology. 2003 Nov;125(5):1364-9
14598252
Gastroenterology. 2009 Apr;136(4):1281-7
19208346
Gastroenterology. 2005 Nov;129(5):1464-72
16285948
Hepatology. 1999 Jun;29(6):1668-71
10347106
J Hepatol. 2002 Feb;36(2):151-6
11830325
Gut. 1967 Oct;8(5):435-48
6057772
Am J Gastroenterol. 2004 Mar;99(3):502-8
15056092
Virchows Arch A Pathol Anat Histol. 1978 Aug 22;379(2):103-12
150690